123 related articles for article (PubMed ID: 33383154)
1. Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma.
Zhang S; Cao M; Hou Z; Gu X; Chen Y; Chen L; Luo Y; Chen L; Liu D; Zhou H; Zhu K; Wang Z; Zhang X; Zhu X; Cui Y; Li H; Guo H; Zhang T
Cancer Lett; 2021 Mar; 501():147-161. PubMed ID: 33383154
[TBL] [Abstract][Full Text] [Related]
2. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
[TBL] [Abstract][Full Text] [Related]
3. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
4. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
5. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma.
Zhang S; Tang D; Zang W; Yin G; Dai J; Sun YU; Yang Z; Hoffman RM; Guo X
Anticancer Res; 2017 Feb; 37(2):465-473. PubMed ID: 28179291
[TBL] [Abstract][Full Text] [Related]
7. Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo.
Zhang HH; Zhang Y; Cheng YN; Gong FL; Cao ZQ; Yu LG; Guo XL
Mol Carcinog; 2018 Jan; 57(1):44-56. PubMed ID: 28833603
[TBL] [Abstract][Full Text] [Related]
8. Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway.
Fan F; Tian C; Tao L; Wu H; Liu Z; Shen C; Jiang G; Lu Y
Biomed Pharmacother; 2016 Oct; 83():704-711. PubMed ID: 27470571
[TBL] [Abstract][Full Text] [Related]
9. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
10. [Anti-angiogenesis effect of arsenic trioxide plus cinobufacin on human hepatocarcinoma transplantation model nude mice].
Liu L; Chen BA; Qin SK
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Jan; 31(1):67-72. PubMed ID: 21434348
[TBL] [Abstract][Full Text] [Related]
11. [Antitumor and anti-angiogenic effects of manumycin on human hepatocellular carcinoma HepG2 xenografts in nude mice].
Zhou JM; Zhu XF; Liu ZC; Fu LW; Yang XP; Liang YJ; Pan QC
Ai Zheng; 2005 Aug; 24(8):935-9. PubMed ID: 16086869
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
14. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
Yoshiji H; Kuriyama S; Fukui H
Tumour Biol; 2002; 23(6):348-56. PubMed ID: 12677092
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activities of Liver-targeting peptide modified Recombinant human Endostatin in BALB/c-nu mice with Hepatocellular carcinoma.
Yan M; Dongmei B; Jingjing Z; Xiaobao J; Jie W; Yan W; Jiayong Z
Sci Rep; 2017 Oct; 7(1):14074. PubMed ID: 29075040
[TBL] [Abstract][Full Text] [Related]
17. Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells.
Wei Y; Yang Q; Zhang Y; Zhao T; Liu X; Zhong J; Ma J; Chen Y; Zhao C; Li J
Oncotarget; 2017 Feb; 8(9):15230-15241. PubMed ID: 28122355
[TBL] [Abstract][Full Text] [Related]
18. Anti‑angiogenic therapy for normalization of tumor vasculature: A potential effect of Buyang Huanwu decoction on nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential.
Min L; Ling W; Hua R; Qi H; Chen S; Wang H; Tang L; Shangguan W
Mol Med Rep; 2016 Mar; 13(3):2518-26. PubMed ID: 26846752
[TBL] [Abstract][Full Text] [Related]
19. The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis.
Enomoto H; Tao L; Eguchi R; Sato A; Honda M; Kaneko S; Iwata Y; Nishikawa H; Imanishi H; Iijima H; Tsujimura T; Nishiguchi S
Sci Rep; 2017 Sep; 7(1):12189. PubMed ID: 28939881
[TBL] [Abstract][Full Text] [Related]
20. Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging.
Liang Q; Kong L; Du Y; Zhu X; Tian J
Exp Mol Med; 2019 Jul; 51(7):1-11. PubMed ID: 31285418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
